rdf:type |
|
lifeskim:mentions |
umls-concept:C0027375,
umls-concept:C0031640,
umls-concept:C0064971,
umls-concept:C0205314,
umls-concept:C0205460,
umls-concept:C0205549,
umls-concept:C0220781,
umls-concept:C0243077,
umls-concept:C0282556,
umls-concept:C0441655,
umls-concept:C0679622,
umls-concept:C1149866,
umls-concept:C1412691,
umls-concept:C1849508,
umls-concept:C1883254
|
pubmed:issue |
14
|
pubmed:dateCreated |
1996-9-10
|
pubmed:abstractText |
A series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans have been synthesized and evaluated for their ability to selectively inhibit PDE IV isolated from guinea pig. Replacement of the 1-phenyl ring by a pyridone ring led to marked improvement of their selectivity for PDE IV over PDE III. The compounds that were most potent and selective involved those bearing an N-alkylpyridone ring at C-1. These compounds also showed potent antispasmogenic activity without causing significant changes in heart rate in the guinea pig. The most potent compound was 6,7-diethoxy-2, 3-bis(hydroxymethyl)-1-[1-(2-methoxyethyl)-2-oxo-pyrid-4-yl]nap hth alene (17f), ED50 values of histamine-induced and antigen-induced bronchoconstriction in the guinea pig being 0.08 and 2.3 mg/kg iv, respectively. This compound was chosen as a candidate for further pharmacological evaluation.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0022-2623
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
5
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2696-704
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8709099-3',5'-Cyclic-AMP Phosphodiesterases,
pubmed-meshheading:8709099-Animals,
pubmed-meshheading:8709099-Anti-Asthmatic Agents,
pubmed-meshheading:8709099-Cyclic Nucleotide Phosphodiesterases, Type 4,
pubmed-meshheading:8709099-Guinea Pigs,
pubmed-meshheading:8709099-Heart Rate,
pubmed-meshheading:8709099-Lignans,
pubmed-meshheading:8709099-Male,
pubmed-meshheading:8709099-Naphthalenes,
pubmed-meshheading:8709099-Parasympatholytics,
pubmed-meshheading:8709099-Phosphodiesterase Inhibitors,
pubmed-meshheading:8709099-Phosphoric Diester Hydrolases,
pubmed-meshheading:8709099-Structure-Activity Relationship
|
pubmed:year |
1996
|
pubmed:articleTitle |
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
|
pubmed:affiliation |
Lead Optimization Research Laboratory, Tanàbe Seiyaku Company, Ltd., Osaka, Japan.
|
pubmed:publicationType |
Journal Article,
In Vitro
|